Anemo Labs provides an electronic olfactory sensor platform that non‑invasively detects volatile organic compounds in urine, sweat and other bodily fluids. The device uses an array of engineered receptors on an olfactory chip and AI‑driven pattern recognition to translate scent signatures into health biomarkers, delivering rapid, low‑cost screening and continuous monitoring for healthcare providers and wellness companies.

Cellestial Health develops brain‑penetrant, orally administered small‑molecule drugs that modulate astrocytic networks to protect neuronal function and halt Parkinson’s disease progression. Its multi‑candidate pipeline targets distinct molecular pathways within astrocytes, aiming for disease‑modifying effects that can extend to other neurodegenerative disorders while adhering to sustainable drug‑discovery practices.

Clyde Hydrogen Systems develops decoupled electrolysis technology that produces high-pressure green hydrogen by separating the generation of hydrogen and oxygen, allowing for greater flexibility and efficiency. This approach addresses the challenges of existing electrolysers, including high costs, safety risks from gas mixing, and the need for mechanical compression.

Excellio Labs builds engineered exosome‑based delivery vehicles that are functionalized with tissue‑specific targeting ligands, enabling precise biodistribution of small molecules, proteins, or nucleic acids. Their scalable platform offers low‑immunogenic, biocompatible vesicles that can be customized for a wide range of therapeutic payloads, helping pharma and biotech companies achieve safer and more effective targeted drug delivery.

Intace develops advanced polymer engineering technology to reprogram natural polymers into high-performance electronic and semiconductor materials. Their patented process creates functional materials that surpass traditional petrochemical options while offering a lower environmental footprint. The initial product is a bioconductive, ESD-safe material designed for semiconductor packaging applications.

Isoform Oncology discovers and targets cancer‑specific protein isoforms created by abnormal RNA splicing, developing antibody‑based biologics that bind these unique tumor‑restricted epitopes. Their platform integrates genomics, transcriptomics, and protein modeling to design isoform‑selective therapeutics that kill cancer cells while sparing normal tissue, addressing unmet needs in resistant and hard‑to‑treat cancers.

This company develops an automated bioprocessing platform that uses AI and data analysis to accelerate the development and manufacturing of biological products. By streamlining bioprocesses, the platform enables faster, cheaper, and higher-quality production for its customers.

This company develops a non-invasive diagnostic platform that captures molecular signals from breath for early and accurate lung cancer detection. Their proprietary process provides high-resolution molecular data without requiring imaging or invasive procedures. The technology aims to create a scalable screening tool accessible in routine primary care settings.

Tangent connects job seekers with current employees at target technology companies for mentorship and direct job referrals. The platform facilitates 1-on-1 support for CV review, interview preparation, and skill development resources. This service bypasses traditional online applications by leveraging internal employee recommendations to increase hiring likelihood.